World J Diabetes 2011 December 15; 2(12): 217-220 ISSN 1948-9358 (online) © 2011 Baishideng. All rights reserved.
Are proton pump inhibitors a new antidiabetic drug? A cross sectional study Diana Boj-Carceller, Pilar Bocos-Terraz, Miguel Moreno-Vernis, Alejandro Sanz-Paris, Pablo Trincado-Aznar, Ramón Albero-Gamboa Diana Boj-Carceller, Alejandro Sanz-Paris, Pablo TrincadoAznar, Ramón Albero-Gamboa, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Pilar Bocos-Terraz, Hormonal Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Miguel Moreno-Vernis, Clinical Documentation and Archives Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Author contributions: Boj-Carceller D and Bocos-Terraz P conceived and designed the study, performed the analysis and interpretation of data and wrote the manuscript; Moreno-Vernis M collected the data and gave administrative support; Sanz-Paris A, Trincado-Aznar P and Albero-Gamboa R gave a critical revision of the article; all authors approved the version of the manuscript to be published. Correspondence to: Diana Boj-Carceller, Dr�, Endocrinology and Nutrition Unit, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. email@example.com Telephone: +34-976-765500-2164 Fax: +34-976-765509 Received: July 4, 2011 Revised: October 2, 2011 Accepted: October 10, 2011 Published online: December 15, 2011
-0.��. People who used PPIs with some type of insu0.��. lin therapy had a HbA1c reduction by -0.�%, 95% CI: -0.12 to -1.��. �or the rest of subgroup analysis based 1.��. on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PP�s seems to be consistentl� associated with better glycemic control in type 2 diabetes. �bA�c reduction observed is similar to incretin-based therapies� © 2011 Baishideng. All rights reserved.
Key words: Proton pump inhibitors; Diabetes mellitus; Drug therap�; ��pogl�cemic agents; �ncretins Peer reviewer: Arulmozhi D Kandasamy, Dr., Department of Pharmacology, University of Alberta, 4-30 Heritage Medical Research Centre, Cardiovascular Research Centre, Edmonton T6G 2S2, Canada Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011; 2(12): 217-220 Available from: URL: http:// www.wjgnet.com/1948-9358/full/v2/i12/217.htm DOI: http:// dx.doi.org/10.4239/wjd.v2.i12.217
AIM: To investigate the e��ect o� proton pump inhibio roton tors �PP�s�� on gl�cemic control ��bA�c�� in t�pe �� diaPP�s�� �� betic patients� METHODS: A cross-sectional stud� o� consecutive inpatients admitted to hospital in an� department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis o� h�pergl�cemic decompensation, diabetic onset or pregnanc�� �t compared �bA�c levels o� those taking PP�s and those not� RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to : 0.12
Proton pump inhibitors (PPIs) have become one of the most commonly prescribed class of drugs whose overall safety profile is unquestionable. PPIs are mainly used to treat symptoms of gastroesophageal reflux disease and gastritis, but also to treat peptic ulcers (duodenal and gastric), drug-induced ulcers and to promote healing of erosive esophagitis. They decrease secretion of gastric acid by blocking
December 15, 2011|Volume 2|Issue 12|
Boj-Carceller D et al � Antidiabetic properties o� proton pump inhibitors
the last enzyme in the system that actively transports acid from gastric parietal...